Articles tagged with Parkinsons Disease
A two-year follow-up study shows participants with advanced PD experienced improvements in tremor, stiffness, slow movement, and balance. The new cell therapy, Spheramine, provided a source of increased dopamine production, maintaining initial gains up to 24 months post-treatment.
A new study suggests that early levodopa treatment may slow the rate of progression in Parkinson's disease. Levodopa treatment showed improved outcomes in patients with early Parkinson's disease compared to placebo.
A study involving 34 Parkinson's patients found that the implant improved their quality of life by an average of 22 percent, with significant improvements in mobility and motor functioning. Patients reported substantial improvements in daily activities such as dressing and preparing meals.
A new study reports remarkable improvements in motor skills and dopamine storage in five Parkinson's patients. The treatment, which administered GDNF directly into the brain, showed a 39% improvement in motor skills and 61% improvement in daily living activities.
Researchers have made a groundbreaking discovery by detecting Parkinson's symptoms on brain scans of living patients. The study, led by Dr. Robert Y. Moore, found positive evidence of nerve cell degeneration in areas controlling attention and wakefulness using PET scans.
Researchers found low-dose exposure to permethrin triggered a process with early onset and persistent effects, while high-level exposures had delayed effects. The study suggests that genetic predisposition may increase the risk of damage from pesticide exposure.
The study found that complex interactions between common gene variants contribute to Parkinson's disease risk in women. Environmental exposures are thought to play a greater role in men, with estrogen reducing the risk of developing the disease in women.
Researchers have discovered a way to control 'badly' behaving neurons in Parkinson's disease, potentially easing symptoms and progression. By blocking potassium channels or eliminating the subunit using gene therapy, high-frequency spiking can be stopped, preserving normal neuronal activity.
Researchers found a significant association between moderate caffeine consumption and reduced risk of Parkinson's disease in postmenopausal women who don't use hormone replacement therapy. However, high caffeine intake increased the risk of PD in women using HRT, suggesting an estrogen-caffeine interaction
The American Academy of Neurology has launched a new online section providing patients and caregivers with practical health care information on various neurological conditions. The Patient Page section aims to give the public access to accurate and reliable information through articles written by practicing neurologists.
A study published in Archives of Neurology found that Parkinson's patients treated with levodopa have higher levels of homocysteine, a risk factor for heart disease and dementia. The study suggests that monitoring homocysteine levels may be necessary for patients at risk of heart disease.
Bradford Parkinson, a pioneer of GPS technology, has been awarded the 2003 Charles Stark Draper Prize for his significant contributions to the development of the original GPS system architecture. He is also recognized for his work on improving GPS accuracy and its applications in various fields.
The study reveals that protein components in the post-synaptic density (PSD) move together in response to neural activity, with a significant percentage undergoing up-and-down regulation. The findings also suggest a high rate of PSD remodeling, with neurons replacing its content multiple times a day.
Researchers discovered that a mutated gene associated with early onset dystonia helps manage protein folding and is normally used as a quality control mechanism. TorsinA's failure to function correctly may lead to protein aggregation, causing neuron malfunction, which is linked to various movement disorders.
A new mouse genetic model exhibits a non-lethal form of spongiform brain disease, characterized by fluid-filled vacuoles and tissue degeneration. The mice lack the same motor coordination problems as affected cattle and are not contagious.
Dr. Ted Fon, a renowned Parkinson's Disease researcher, has been awarded a significant grant by the Michael J. Fox Foundation to investigate the role of protein degradation in the disease. The grant aims to enhance understanding of parkin function and its potential impact on dopamine nerve cell death.
Researchers have found a new Parkinson's drug to be effective in improving symptoms, with participants receiving 1mg of Rasagiline showing significant improvements compared to those on 2mg. The study calls for further research to evaluate the long-term effects of Rasagiline on the progression of the disease.
A new testing method for Huntington's disease (HSS) has been discovered by researchers at Oregon Health & Science University and UCSF. The test uses magnetic resonance imaging (MRI) to identify the 'eye of the tiger sign' in patients with PANK2 mutations, a gene linked to HSS and Parkinson's disease.
A study of Parkinson's patients found that those with advanced disease are at greater risk for motor vehicle collisions due to motor and cognitive dysfunction. The study also revealed no correlation between self-reported moving violations and total collisions on the simulator.
New research from University of Minnesota presents promising findings on unrelated donor transplants, including a study showing improved survival rates and quality of life for leukemia/lymphoma patients. Another study explores the use of bone marrow-derived stem cells to treat Parkinson's disease.
A new class of drugs may prevent neurodegenerative disorders by fortifying neurons before disease onset. Geldanamycin, a natural antibiotic, boosts molecular chaperone activity, protecting against alpha-synuclein toxicity in Parkinson's disease.
Researchers at Thomas Jefferson University have successfully converted human neural stem cells into dopamine-making neurons in a laboratory setting. Approximately 25% of the stem cells were able to produce the enzyme tyrosine hydroxylase, which is necessary for dopamine production. The breakthrough could potentially lead to the develop...
Researchers have found that high-frequency stimulation of the brain can alleviate obsessive-compulsive disorder (OCD) symptoms in patients with Parkinson's disease. Two patients who underwent electrode implantation showed significant improvement in compulsive behaviors, suggesting a potential therapeutic approach for severe OCD.
A large cohort study found that high dietary vitamin E intake was associated with a significantly lower risk of developing Parkinson's disease. However, the use of vitamin E or C supplements and multivitamins showed no protective effect on Parkinson's risk. The results suggest that other lifestyle factors may also play a role in reduci...
A landmark study shows that high doses of coenzyme Q10 can slow the progression of Parkinson's disease, measured by movement difficulty or disability. The study found significant reductions in motor disabilities, mental function, and mood among participants taking the nutrient.
A national clinical trial with 80 Parkinson's patients showed that high-dose coenzyme Q10 slowed functional decline by 44%, particularly in everyday activities. The therapy needs to be tested in a larger trial before it can be recommended.
A phase II study found that coenzyme Q10 can slow the rate of functional decline in Parkinson's disease by improving mitochondrial function and energy-producing reactions. The study showed that higher doses of coenzyme Q10, up to 1,200 mg/day, were safe and more effective than lower doses.
Researchers have developed a new surgical procedure for Parkinson's disease, bilateral subthalamotomy, which has shown promising results in improving motor symptoms and activities of daily living. After two years of follow-up, patients exhibited approximately 50% improvement in motor symptoms and significant reduction in medication doses.
A new study using gene therapy has shown promise in treating Parkinson's disease by 'resetting' overactive brain cells. The therapy may arrest or delay disease progression, offering a safer and more powerful alternative to current treatments.
Researchers successfully used gene therapy to change the brain's circuitry in rats with Parkinson's disease, producing nearly 70% fewer symptoms. The treatment involves altering glutamate and GABA signaling pathways to protect dopamine neurons from deterioration.
A Rutgers University researcher found that dopamine loss causes brain connections to reorganize, leading to impaired motor control. The study suggests that this permanent change may explain why current treatments fail to restore complex movements in Parkinson's disease patients.
Emory University will lead a new center studying the relationship between environmental agents and Parkinson's disease, with research focusing on pesticides, organochlorine insecticides, and genetic causes of PD. The center aims to develop strategies for prevention and treatment.
The National Institute of Environmental Health Sciences (NIEHS) is launching a $20 million effort to pinpoint environmental triggers of Parkinson's disease. Three centers will conduct independent research, including the University of California at Los Angeles, Emory University, and The Parkinson's Institute.
Despite expected global warming impacts, a NASA study reveals an increase in Antarctic sea ice coverage, with the area lengthening by at least one day per year spanning around 5.6 million square kilometers.
A new Medicines Information Helpline has been launched in the UK to provide independent expert advice on medicines for patients with Parkinson's disease. The helpline, staffed by experienced pharmacists, aims to address the need for reliable information on medication management for this growing population.
A study by the American Academy of Neurology found that individuals with depression are more likely to develop Parkinson's disease than those without depression. The researchers suggest that low levels of serotonin in the brain may contribute to both depression and Parkinson's disease, increasing the risk of developing the latter.
Computer model simulates brain cell firing patterns to explain Parkinson's tremors. The model suggests that a synchronized pattern of signals, rather than just increased frequency, is responsible for the characteristic tremors of the disease.
Researchers found significant loss of sympathetic nerve endings in patients with Parkinson's disease (PD), even those without orthostatic hypotension. The study suggests that PD is caused by widespread sympathetic nerve damage, unrelated to treatment with levodopa.
Researchers found that Parkinson's patients who developed dementia had a significantly higher risk of death, regardless of hallucination or depression status. The study also revealed that incident dementia and disease severity were independently associated with an increased risk of mortality.
A study by American Academy of Neurology found that rivastigmine significantly reduced hallucinations and improved cognitive abilities in Parkinson's patients. The medication also showed benefits in reaction times, attention, and caregiver distress.
A Phase I trial has shown that retinal cell implantation can improve motor function in advanced Parkinson's disease patients by nearly 50 percent, according to researchers at Emory University. The implanted cells provide a source of increased dopamine production, helping to alleviate symptoms such as tremors and stiffness.
Researchers at Emory University Health Sciences Center have found a potential link between low testosterone levels and non-motor symptoms of Parkinson's disease in men. Testosterone replacement therapy showed significant improvement in patients with refractory symptoms, including fatigue, depression, anxiety, and decreased libido.
A study of 32 patients with advanced Parkinson's disease found that fetal cell transplants improved symptoms, with the effects being directly proportional to the results experienced prior to transplant. The transplants also showed a significant improvement in dopamine activity in the brain, which stabilized over time.
A study led by Kenneth Marek found that pramipexole slows dopaminergic neuronal degeneration compared to levodopa in early Parkinson's patients. Most patients will be treated with both medications, and further research is needed to assess the clinical impact of these findings.
A study found that green tea extract polyphenol can block the uptake of dopamine, providing a potential protective mechanism against Parkinson's disease. The results suggest that polyphenol can inhibit the uptake of dopamine or neurotoxin MPP+ by blocking dopamine transporter.
Researchers successfully treated rats with chemical-induced Parkinson's disease using gene therapy, restoring normal limb movement. The treatment involves delivering two corrective genes into a specific brain region to prime the production of dopamine, which coordinates limb movements.
Despite being a significant advancement in Parkinson's disease treatment, only 7% of eligible patients in G5 European countries have received deep brain stimulation therapy. Inconsistent funding support and low awareness among general practitioners are major barriers to access.
The Michael J. Fox Foundation awards a $10 million grant to Jeffrey Kordower, PhD, of Rush University Medical Center, to develop embryonic stem cell lines for Parkinson's disease treatment. The goal is to create dopaminergic cells that can be used in research and potentially lead to new treatments.
Two women with Parkinson's disease experienced hair loss while on dopamine agonists pramipexole and ropinirole. After discontinuing these medications and switching to new treatments, their hair growth resumed in both cases.
Researchers at Duke University Medical Center have identified chromosomal regions linked to the age at onset of Alzheimer's and Parkinson's diseases. The study found evidence for age-at-onset genes on chromosomes 10, 1, 4, and 8, which could lead to new avenues of research to delay disease onset.
Researchers found that mice fed a folate-deficient diet developed severe Parkinson-like symptoms, while those with adequate amounts of the vitamin protected their brain cells from damage. Folate deficiency may contribute to increased toxin-induced damage to dopamine-producing neurons.
The American Academy of Neurology has reviewed new drugs for treating Parkinson's disease, but found that they do not offer significant advantages over existing treatments. Current treatment guidelines remain unchanged, emphasizing the importance of individualized treatment decisions.
The largest clinical trial ever of Parkinson's disease will be conducted by Professor Karl Kieburtz, with over 3,000 patients participating from 42 sites across North America. The five-year study aims to test the effectiveness of various substances in slowing disease progression.
A protective protein called a chaperone suppresses the toxicity of alpha-synuclein, a protein associated with Parkinson's disease. The study found that augmenting levels of Hsp70 corrected the deficit and overcame the toxic effect of loss of chaperone function.
A team of Penn researchers found that molecular chaperones can block the progression of neurodegenerative diseases like Parkinson's by preventing neuronal decay in Drosophila melanogaster. The study suggests that activating these molecules may be an effective approach to treating several human neurodegenerative diseases.
A study published in Neurology found that electrical brain stimulation increased 'on' motor function by 29 percent and improved 'off' motor function by 38 percent in Parkinson's patients. The treatment reduced the severity of fluctuations in motor symptoms, allowing patients to complete tasks faster and improve their overall mobility.
The study provides strong evidence that several genes influence the development of late-onset Parkinson's and that age at onset and response to levodopa may be useful discriminators for genetic origins. Researchers detected evidence for genetic linkage to five distinct regions on chromosomes 5, 6, 8, 9, and 17.
A study led by Dr. Jeffery M. Vance found significant evidence of linkage between the tau gene and late-onset Parkinson's in three single nucleotide polymorphisms. The research suggests that normal variations in the tau protein may make individuals more susceptible to the disease.
Researchers at UCSD suggest that naturally occurring molecules called beta-synucleins (b-synucleins) may inhibit the excessive accumulation of Lewy bodies, which are characteristic of Parkinson's disease. In mice studies, b-synuclein was shown to block the formation of these abnormal deposits.
Hopkins researchers found that parkin, aS and synphilin interact, with mutations disturbing this interaction leading to Lewy body formation and nerve cell death. Understanding these interactions may help identify targets for new treatments.